Mid-America Apartment Communities, Inc. Q3 adjusted earnings Beat Estimates

Mid-America Apartment Communities, Inc. (MAA) announced a profit for its third quarter that climbed from last year.

The company’s bottom line came in at $83.56 million, or $0.73 per share. This compares with $58.99 million, or $0.52 per share, in last year’s third quarter.

Analysts had expected the company to earn $0.65 per share, according to figures compiled by Thomson Reuters. Analysts’ estimates typically exclude special items.

The company’s revenue for the quarter rose 6.9% to $452.58 million from $423.20 million last year.

Mid-America Apartment Communities, Inc. earnings at a glance:

-EPS (Q3): $1.56 vs. $1.40 last year.
-Analysts Estimate: $0.65
-Revenue (Q3): $452.58 Mln vs. $423.20 Mln last year.

-Guidance:
Full year EPS guidance: $6.20 to $6.32

Coca-Cola is about to report earnings. Here's what to expect

Coca-Cola is expected to report fiscal third-quarter earnings before the market opens on Wednesday.

Here's what Wall Street analysts surveyed by Refinitiv are expecting:

• Earnings per share: 58 cents
• Revenue: $9.75 billion

Like most food and beverage companies, Coke is seeing higher commodity and transportation costs. Last quarter, however, Chief Financial Officer John Murphy said that the company was feeling good about the rest of the year. Coke said it planned to raise prices and use productivity levers to manage volatility in the second half of 2021.

For the full year, Coke has been calling for organic revenue growth of 12% to 14%, with adjusted earnings per share growth of 13% to 15%.

RBC Capital Markets analyst Nik Modi said in a note to clients ahead of Coke's earnings report that other challenges to consider are product availability and labor constraints. Modi said that his team's recent channel checks suggest that bottlers are having a more difficult time getting products to market due to driver shortages, primarily in pockets of the United States and Europe.

Coke's stock has dropped about 1% year to date. The company has a market value of $235 billion.

—CNBC's Amelia Lucas contributed to this reporting.

Teck Resources Q3 Profit Climbs

Teck Resources Limited (TECK, TECK_A.TO, TECK_B.TO) reported that its third-quarter profit attributable to shareholders climbed to C$816 million or C$1.51 per share from C$61 million or C$0.11 per share in the previous year.

Adjusted profit attributable to shareholders was C$1.02 billion or C$1.88 per share compared to C$130 million or C$0.24 per share last year.

Revenues for the quarter grew to C$3.97 billion from C$2.29 billion last year.

The company continues to expect first production in the second half of 2022.

The company noted that its previously issued 2021 annual guidance is unchanged.

CDC Recommends 4th Booster Covid Vaccine Dose For Immunocompromised People

The Center for Disease Control and Prevention in the U.S recently updated its Covid-19 guidelines and said that immunocompromised people in the country may require a fourth dose of the COVID-19 vaccine.

As per the revised guidelines, any person who is above 18 years and has already got two mRNA COVID-19 vaccine shots and also received an additional mRNA vaccine dose can receive the single COVID-19 booster dose, at least six months after the third mRNA vaccine dose. The vaccine can be any one of the following- Pfizer/BioNTech, Moderna or Johnson & Johnson.

The CDC said that those people who have received both vaccine shots and are slightly or highly immunocompromised, with a gap of more than 28 days since the second dose, must take an additional mRNA dose. Next, after a period of six months, the immunocompromised people must secure a single COVID-19 booster dose.

The CDC said, “In such situations, people who are moderately and severely immunocompromised may receive a total of four COVID-19 vaccine doses.”

People suffering from immunocompromising conditions or those who take immunosuppressive medications or therapies are more prone to severe Covid-19. The CDC observed that it had seen reduced effect of the vaccine in immunocompromised participants than those who are not.

FDA acting commissioner Dr. Janet Woodcock said, “The availability of these authorized boosters is important for continued protection against COVID-19 disease.”

Conmed Corp. Q3 adjusted earnings Beat Estimates

Conmed Corp. (CNMD) revealed earnings for its third quarter that rose from the same period last year.

The company’s earnings came in at $14.95 million, or $0.47 per share. This compares with $6.85 million, or $0.23 per share, in last year’s third quarter.

Analysts had expected the company to earn $0.75 per share, according to figures compiled by Thomson Reuters. Analysts’ estimates typically exclude special items.

The company’s revenue for the quarter rose 4.6% to $248.83 million from $237.84 million last year.

Conmed Corp. earnings at a glance:

-Earnings (Q3): . vs. . last year.
-EPS (Q3): $0.80 vs. $0.88 last year.
-Analysts Estimate: $0.75
-Revenue (Q3): $248.83 Mln vs. $237.84 Mln last year.

-Guidance:
Full year EPS guidance: $3.18 – $3.23

Bryant Ranch Recalls Methocarbamol 500mg Bottles

Byant Ranch has issued a voluntary recall of Methocarbamol 500mg tablets due to mislabeling with the incorrect strength.

The bottles labeled as Methocarbamol 500mg tablets have been found to contain Methocarbamol 750mg tablets.

If a patient takes a 750mg Tablet of Methocarbamol instead of the prescribed 500mg Tablets, it potentially could result in Excessive Central Nervous System depression which may result in nausea, sedation, fainting, falls, seizure, coma, and death. However, the company has not received any adverse events related to the recall.

The affected Methocarbamol 500mg lots include the following Lot Number 163935/ Exp. Date 10/22.

Methocarbamol tablets is used together with rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions.